Adalvo has successfully launched Rivaroxaban across Asia, the Middle East, North America, and in certain countries in Europe*, in collaboration with multiple strategic partners, highlighting its ability to execute complex, high-value launches across global markets.
Developed based on the reference brand Xarelto, Rivaroxaban is indicated for the prevention of atherothrombotic events in adult patients following an acute coronary syndrome (ACS), or those with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD).
As a blockbuster product, Rivaroxaban continues to play a major role in cardiovascular risk management. According to IQVIA, global MAT sales of Rivaroxaban reached approximately $13 billion in 2024, highlighting its ongoing clinical relevance and market stability.
This launch strengthens Adalvo’s commitment to delivering partner-ready, technically complex products across both established and emerging markets. With a strong global network and proven execution capabilities, Adalvo continues to support its partners in expanding access to essential therapies across therapeutic areas.
To explore licensing opportunities or access Adalvo’s cardiovascular portfolio, contact the team today.
(*) Adalvo has supported the launch by its Partners in European countries where there’s no patent protection or patent has been found invalid, decisions may be under appeal.